Modulatory Effect of Bolinaquinone, a Marine Sesquiterpenoid, on Acute and Chronic Inflammatory Processes

  1. Rut Lucas1,
  2. Clelia Giannini2,
  3. Maria Valeria D'auria2 and
  4. Miguel Payá1
  1. 1Departamento de Farmacologı́a (R.L., M.P.), Universidad de Valencia, Facultad de Farmacia, Valencia, Spain; and 2Dipartimento di Chimica delle Sostanze Naturali (C.G., M.V.D.), Università degli Studi di Napoli, Naples, Italy
  1. Dr. Miguel Payá, Departamento de Farmacologı́a, Universidad de Valencia, Facultad de Farmacia, Av. V. Andrés Estelles s/n, 46100 Burjassot, Valencia, Spain. E-mail:miguel.paya{at}uv.es
 
Next Section

Abstract

The marine metabolite bolinaquinone is a novel inhibitor of secretory phospholipase A2 (sPLA2), with a potency on the human synovial enzyme (group II) higher than that of manoalide. This activity on the sPLA2 was confirmed in vivo in the 8-h zymosan rat air pouch on the secretory enzyme accumulation in the pouch exudate. Additionally, bolinaquinone decreased potently the synthesis and release of leukotriene B4 (LTB4) in calcimycin (A23187)-stimulated human neutrophils as a consequence of the inhibition of 5-lipoxygenase activity, as well as PGE2 and NO production on zymosan-stimulated mouse peritoneal macrophages. This compound exerted anti-inflammatory effects by topical and oral routes on the mouse ear edema induced by 12-O-tetradecanoylphorbolacetate, with ID50values of 76.7 μg/ear and 5.6 mg/kg, respectively, with a significant decrease in PGE2, LTB4, and tumor necrosis factor-α (TNF-α) levels being more effective than indomethacin. This effect was confirmed in the mouse paw carrageenan edema after oral administration. Moreover, bolinaquinone was able to reduce the inflammatory response of adjuvant arthritis by inhibiting PGE2, NO, and TNF-α production in paw homogenates without affecting PGE2 levels in the stomach. Additionally, bolinaquinone inhibited inducible nitric oxide synthase expression and reduced the degree of bone resorption, soft tissue swelling, and osteophyte formation.

Phospholipases A2 (PLA2) are a class of lipolytic enzymes that release arachidonic acid from thesn-2 position of phospholipids as a previous step for the synthesis of a great variety of eicosanoids and platelet-activating factor (Balsinde et al., 1999). Mammalian PLA2s are divided in two major classes according to their molecular mass and location: intracellular PLA2 and secreted (sPLA2). Type IIA sPLA2(sPLA2-IIA), the best studied enzyme of sPLA2, has been detected at high levels in various inflamed sites, suggesting its involvement in pathogenesis of the inflammatory responses. Moreover, the enzyme concentration in serum tissues correlates with disease severity in several immune-mediated inflammatory pathologies, such as rheumatoid arthritis, septic shock, psoriasis, Crohn's disease, and asthma (Vadas and Pruzanski, 1986;Minami et al., 1994). The proinflammatory actions of sPLA2-IIA in local inflammatory processes have been verified by injecting this enzyme (Murakami et al., 1990;Bomalaski and Clark, 1993) into various inflamed sites of experimental models. Besides, inflammatory cytokines increase group II PLA2 synthesis and secretion by rheumatoid synovial fibroblasts and other cells (Bomalaski and Clark, 1993;Pfeilschifter et al., 1993) causing a parallel increase in prostaglandin E2 (PGE2) production (Jacques et al., 1997). Group II sPLA2has been reported to release arachidonic acid in some systems and may provide the substrate for both cyclooxygenase (COX) and 5-lypoxigenase (5-LO) product formation in mouse bone marrow-derived mast cells (Fonteh et al., 1994).

Marine organisms are a rich source of molecules exhibiting PLA2 inhibitory properties in vitro, mainly on secretory enzymes (Garcia-Pastor et al., 1999a,b). In a previous study (Ferrándiz et al., 1994), we reported that avarol, a sesquiterpenoid hydroquinone with weak inhibitory properties against human synovial PLA2, and its quinone derivative, avarone, potently inhibited paw edema induced by carrageenan, as well as ear edema induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). Bolinaquinone, a sesquiterpenoid derivative sharing both hydroquinone and quinone moieties in its chemical structure (Fig.1), was recently isolated from aDysidea sp. sponge (Giannini et al., 2001), showing a characteristic in vitro inhibitory profile against different sPLA2 belonging to the group I (porcine pancreatic enzyme), group IIA (human synovial), and group III (bee venom enzyme) without any effect on cytosolic PLA2. Its potency was higher than that of manoalide, one of the best-known PLA2 inhibitors (Soriente et al., 1999; Giannini et al., 2001).

Figure 1
View larger version:
Figure 1

Chemical structure of bolinaquinone.

It is known that prostaglandins and nitric oxide (NO) are ubiquitous mediator systems exerting numerous vascular and inflammatory effects (Kaur and Halliwell, 1994; Kang et al., 1996). In addition, NO is also able to enhance the production of a variety of mediators, such as TNF-α and IL-1β, which participate in the macrophage-dependent inflammatory response (Marcinkiewicz et al., 1995).

The purpose of the present study was to investigate the modulatory effect of this sponge metabolite on acute and chronic inflammatory models, as well as to define its mechanism of action on the basis of its potential modulation of cytokine production, generation of nitric oxide, and eicosanoid metabolites, including prostaglandins and leukotrienes. This is the first report concerning the pharmacological properties of this compound.

Previous SectionNext Section

Materials and Methods

Reagents.

Bolinaquinone was isolated from the spongeDysidea sp. following known procedures recently published (Giannini et al., 2001). [5,6,8,11,12,14,15(n)-3H]PGE2, [5,6,8,9,11,12,14,15(n)-3H]LTB4, [9,10-3H]oleic acid, and the enhanced chemiluminescence system were from Amersham Iberica (Madrid, Spain). COX-2 and inducible nitric oxide synthase (iNOS) polyclonal antisera were purchased from Cayman Chemical Co. (Ann Arbor, MI). The peroxidase-conjugated goat anti-rabbit IgG was purchased from DAKO (Copenhagen, Denmark). Mycobacterium butyricum was obtained from Difco (Detroit, MI). The remainder of reagents were from Sigma-Aldrich (St. Louis, MO).

Preparation of Human Neutrophils.

Leukocytes were obtained and purified as previously described (Bustos et al., 1995). Viability was greater than 95% by the trypan blue exclusion test. The mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan (Gross and Levi, 1992) was used to assess the possible cytotoxic effect of bolinaquinone on human neutrophils.

Synthesis and Release of LTB4 by Human Neutrophils.

A suspension of human neutrophils (5 × 106cells/ml) was preincubated with test compound or vehicle and then stimulated with the calcium ionophore A23187 (1 μM) for 10 min at 37°C. LTB4 levels in supernatants were measured by radioimmunoassay (Hoult et al., 1994). High speed (100,000g) supernatants from sonicated human neutrophils were obtained and incubated in appropriate conditions with 10 μM arachidonic acid to assess 5-lipoxygenase activity (Tateson et al., 1988).

Isolation and Culture of Mouse Peritoneal Macrophages.

Female Swiss mice weighing 25 to 30 g were used to obtain highly purified peritoneal macrophages. Cells were harvested by peritoneal lavage 4 days after i.p. injection of 1 ml of 10% thioglycollate broth. Cells were resuspended in culture medium (120 mM NaCl, 4.7 mM KCl, 1.2 mM CaCl2 × 7H2O, 1.2 mM KH2PO4, 25 mM NaHCO3, 10 mM HEPES, 1 mM arginine, and 10 mM glucose) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and incubated at 37°C for 2 h. The adherent cells were used to perform the following experiments. Cytotoxicity was assessed by the reduction of MTT as above.

iNOS and COX-2 Activity in Mouse Peritoneal Macrophages.

Peritoneal macrophages (4 × 105cells/well) were preincubated with test compounds or vehicle for 30 min and then stimulated with zymosan (0.1 mg/ml) in 96-well culture plate at 37°C for 18 h in the presence of test compounds or vehicle. The nitrite concentration in culture supernatants, as a reflection of NO release, was determined fluorometrically (Misko et al., 1993). PGE2 levels were determined by radioimmunoassay (Hoult et al., 1994).

Mouse Ear Edema.

All studies were performed in accordance with the Declaration of Helsinki and the European Community guidelines for the handling and use of laboratory animals. The protocols were approved by the institutional Animal Care and Use Committee. TPA (2.5 μg) dissolved in 20 μl of acetone was applied in 10-μl volumes to both inner and outer surfaces of the right ear of Swiss mice (20–25 g). Test compounds were applied topically in acetone 30 min before TPA administration or orally in olive oil 1 h before TPA. The animals were killed by cervical dislocation after 4 h, and equal sections of both ears were punched out and weighed. The increase in the weight of the right ear punch over the left indicated the edema (Carlson et al., 1985). The ear sections were homogenized in 750 μl of saline, and after centrifugation at 1200g for 15 min at 4°C, the PGE2 and LTB4 content was determined as above. TNF-α levels were quantified by time-resolved fluoroimmunoassay (Pennanen et al., 1995).

Carrageenan Paw Edema.

The anti-inflammatory activity of bolinaquinone was assessed by the carrageenan paw edema test in mice according to the method of Sugishita et al. (1981). This compound (3.1, 6.3, 12.5, and 25 mg/kg), indomethacin (5 mg/kg) or vehicle (olive oil) was administered orally (0.3 ml) 1 h before injection of carrageenan (0.05 ml; 3% w/v in saline) into the subplantar area of the right hind paw. The volumes of the injected and contralateral paws were measured at 1, 3, and 5 h after induction of edema by using a plethysmometer (Ugo Basile, Comerio, Italy). The volume of edema was expressed for each animal as the difference between the carrageenan-injected and contralateral paws. After the last determination of paw edema (5 h), the animals were killed by cervical dislocation, and the right hind paws were homogenized in 2 ml of saline. Aliquots of supernatants were used to determine PGE2 and LTB4 as above.

Rat Air Pouch.

The air pouch procedure was performed in male Wistar rats (120–150 g), as previously described (Edwards et al., 1981). Six days after the initial air injection, 1 ml of sterile saline or 1 ml of 1% w/v zymosan in saline was injected to the air pouch. In the 8-h zymosan-stimulated air pouch, bolinaquinone at 6.3 mg/kg was administered orally in olive oil 30 min before zymosan injection. After 8 h, the animals were killed by cervical dislocation, and the exudate in the pouch was collected with 1 ml of saline. Leukocytes present in exudate in the pouch were measured using a Coulter counter. After centrifugation of exudates (1,200g at 4°C for 10 min), the supernatants were used to measure PGE2and LTB4 as above. Secretory phospholipase A2 activity was determined in supernatants previous purification by acid treatment (Bolognese et al., 1995). Aliquots of supernatants were subjected to acid extraction by exposure to equal volumes of 0.36 N H2SO4 for 1 h at 4°C. After treatment, the samples were readjusted to pH 7.4 by addition of 2 M Tris, pH 10, the precipitate was removed by centrifugation at 10,000g for 5 min at 4°C. Supernatants were incubated at 37°C for 15 min in the presence of 10 μl of autoclaved [3H]oleate-labeled membranes ofE. coli (Franson et al., 1974).

Adjuvant-induced Arthritis.

Adjuvant arthritis was elicited in female Lewis rats (175–200 g) by injection of 0.1 ml ofM. butyricum (10 mg/ml) in mineral oil into the base of the tail (Taurog et al., 1988). Paw volumes were measured at the beginning of the experiment by using a water displacement plethysmometer. The magnitude of the inflammatory response was evaluated by measuring the volume of both hind paws at day 17. Animals with edema values of 1.1 ml larger than normal paws were then randomized into treatment groups. Bolinaquinone or vehicle (olive oil) (6.3 mg/kg) was administered p.o. twice daily, and the edema in hind paws was measured on days 17 to 24. Serum was collected on the last day of the experiment (day 25) for the determination of PGE2 and nitrite content. Rats were placed on a radiographic box at a distance of 90 cm from an X-ray source. Radiographic analysis of arthritic hind paws was performed by X-ray machine (Univet LX160; Multimage, Cavarie, Italy) with a 40-kW exposition for 0.01 s. After death, hind paws were amputated above the ankle and homogenized in 2.5 ml of 10 mM HEPES buffer, pH 7.4, containing 0.32 M sucrose, 100 μM EDTA, 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, and 100 μM leupeptin. After centrifugation at 2000g for 15 min at 4°C, supernatants were used for the determination of PGE2, nitrite, and TNF-α levels as above. Stomachs were homogenized in 2.0 ml of methanol and aliquots of supernatants were used to determine the content of PGE2.

Western Blot Assay.

The supernatants from homogenized and centrifugated paws were sonicated and centrifugated at 10,000g for 15 min at 4°C. Supernatant protein was determined, and 25 μg of protein was loaded on 12% SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene diflouride membranes for 90 min at 125 mA. Membranes were blocked in phosphate-buffered saline-Tween 20 containing 3% w/v unfatted milk. For iNOS, membranes were incubated with anti-iNOS polyclonal antibody (1:1,000 dilution); for COX-2, membranes were incubated with specific anti-COX-2 polyclonal antiserum (1:1,000 dilution). Blots were washed and incubated with peroxidase-conjugated goat anti-rabbit IgG (1:20,000 dilution). The immunoreactive bands were visualized using an enhanced chemiluminescence system.

Statistical Analysis.

The results are shown as mean ± S.E.M. for n experiments. IC50 values were calculated from at least four significant concentrations (n = 6). Statistical evaluation included one-way analysis of variance followed by Dunnett's t test for multiple comparisons.

Previous SectionNext Section

Results

Effect on Synthesis and Release of LTB4 and Other Enzyme Activities in Vitro.

We first tested the in vitro effect of bolinaquinone on various enzymes involved in the synthesis of inflammatory mediators, such as 5-LO, COX-2, and iNOS. As shown in Fig.2, bolinaquinone inhibited in a concentration-dependent manner LTB4 generation and release in A23187-stimulated human neutrophils, as well as 5-LO activity in high-speed supernatants from human neutrophils, with IC50 values of 2.1 and 1.3 μM. The reference compound ZM 230,487, a selective inhibitor of 5-LO, showed an IC50 value of 0.1 μM. In addition, as indicated in Table 1, bolinaquinone at 1 μM, coincubated with zymosan, reduced PGE2 and nitrite accumulation around 50% in culture medium from zymosan-stimulated mouse peritoneal macrophages with a lesser potency than the reference compound dexamethasone. It is noteworthy that bolinaquinone caused neither cellular toxicity on human neutrophils nor on mouse peritoneal macrophages at the concentrations used, as determined by reduction of MTT to formazan (data not shown).

Figure 2
View larger version:
Figure 2

Effect of bolinaquinone on 5-LO activity (▴) by high supernatants from human neutrophils and LTB4 release (▪) by A23187-stimulated human neutrophils. All data values represent the mean ± S.E.M. (n = 6). ★★,p < 0.01.

View this table:
Table 1

Effect of bolinaquinone and dexamethasone on iNOS and COX-2 activities on zymosan-stimulated murine peritoneal macrophages

Effect on Mouse Ear Edema.

Bolinaquinone inhibited potently mouse ear edema induced by TPA after topical (Fig.3A) and oral administration (Fig.4). The effect was dose-related with an approximated inhibitory dose 50% (ID50) of 76.7 μg/ear for topical administration and 5.6 mg/kg for oral administration. The topical inflammatory response also showed high levels of PGE2, LTB4, and TNF-α in the ear homogenates of control animals treated with TPA (Fig. 3, B–D). Treatment with bolinaquinone resulted in a significant decrease in PGE2, LTB4, and TNF-α levels and was more effective than indomethacin in this model.

Figure 3
View larger version:
Figure 3

Topical effect of bolinaquinone and indomethacin on the mouse ear edema model induced by TPA. Data represent the mean ± S.E.M. (n = 6). ★, p < 0.05; ★★, p < 0.01 with respect to TPA control group. Test compounds (μg/ear) were applied topically in acetone 30 min before TPA administration. A, ear edema; B, PGE2 levels in ear homogenates; C, LTB4 levels in ear homogenates; D, TNF-α in ear homogenates.

Figure 4
View larger version:
Figure 4

Antiedematogenic effect of bolinaquinone, dexamethasone, and indomethacin by oral route on the mouse ear edema model induced by TPA. Data represent the mean ± S.E.M. (n = 6). ★★, p < 0.01 with respect to TPA control group. Test compounds (in milligrams per kilogram) were administered p.o. 1 h before TPA administration. Dexa, dexamethasone; Indo, indomethacin.

Effect on Mouse Paw Edema.

Intraplantar injection of carrageenan to mice caused an inflammatory reaction. Oral pretreatment (1 h before carrageenan) with 3.1, 6.3, 12.5, or 25 mg/kg bolinaquinone reduced hind paw swelling (Fig. 5A). This inhibitory effect was observed at the three time points considered and was as effective as indomethacin in this model. The last evaluation of edema (5 h) was followed by killing the animals, and the paws injected with carrageenan were homogenized to determine the levels of PGE2 and LTB4 (Fig. 5, B and C). The results indicate that bolinaquinone strongly reduced the levels of LTB4 at the doses assayed, whereas this compound reduced the levels of PGE2 at the doses of 25 and 12.5 mg/kg. Indomethacin clearly reduced the levels of this prostanoid and, to a much lesser extent, LTB4levels.

Figure 5
View larger version:
Figure 5

Effect of bolinaquinone and indomethacin on the carrageenan mouse paw edema model. Data represent the mean ± S.E.M. (n = 6). ★, p < 0.05; ★★, p < 0.01 with respect control group. Test compounds (in milligrams per kilogram) were administered p.o. 1 h before the injection of carrageenan. A, paw edema at 1, 3, and 5 h after induction of inflammation; B, PGE2 levels in paw exudates; C, LTB4 levels in paw exudates.

Effect on Rat Air Pouch.

We tested the effect of this marine compound on an animal model in which high levels of secretory type II sPLA2 is generated (Payá et al., 1996). As shown in Fig. 6, bolinaquinone administered orally at 6.3 mg/kg was able to reduce significantly PLA2 activity present in the 8-h zymosan-injected rat air pouch, as well as PGE2 and LTB4 levels, without affecting the cellular migration.

Figure 6
View larger version:
Figure 6

Inhibitory effect of bolinaquinone administered orally 30 min before zymosan (6.3 mg/kg) on cellular migration, PGE2 production, LTB4 production, and sPLA2 activity in the 8-h zymosan-injected rat air pouch model. Data represent percentages of inhibition and the mean ± S.E.M. (n = 6). ★★,p < 0.01 with respect to control group. Control cell migration = 56.7 × 106 ± 9.4 × 106 cells/ml. Control PGE2 production = 21.6 ± 1.0 ng/ml. Control LTB4 production = 22.6 ± 1.7 ng/ml. Control sPLA2 activity = 318.2 ± 10.7 pmol of oleic acid/20 μg/15 min.

Effect on Adjuvant Arthritis.

The anti-inflammatory properties of this marine compound were also tested in a model of chronic inflammation, the established adjuvant arthritis. The administration of 6.3 mg/kg twice daily from day 17 to 24 after adjuvant injection to animals with developed arthritis significantly reduced mean paw edema from day 19 to 24 after adjuvant (Fig.7A) and protected from body weight and spleen weight loss as it was observed for the dexamethasone reference group. At the end of the experiment (day 25), the levels of the inflammatory mediators (PGE2, nitrite, and TNF-α) in different tissues were measured. Bolinaquinone reduced significantly PGE2 in paw but did not modify PGE2 in serum and stomach homogenates as it did with dexamethasone. Nevertheless, the stomachs of the animals treated with dexamethasone showed redness, which was absent in the rats treated with bolinaquinone. Interestingly, bolinaquinone was very effective reducing nitrite and TNF-α in serum and in paws (Fig.8, B and C).

Figure 7
View larger version:
Figure 7

Effect of bolinaquinone (6.3 mg/kg) and dexamethasone (2 mg/kg) on the development of adjuvant-induced arthritis in Lewis rats. Compounds were administered twice daily on days 17 to 24, and paw tissues were recovered on day 25 after adjuvant injection for analysis. Data represent the mean ± S.E.M. (n = 6). ★, p < 0.05; ★★, p < 0.01 with respect to the vehicle-treated arthritic group. A, paw edema progression; B, body weight progression; C, spleen weight on day 25 after adjuvant injection.

Figure 8
View larger version:
Figure 8

Effect of bolinaquinone (6.3 mg/kg) and dexamethasone (2 mg/kg) on PGE2, nitrite and TNF-α levels in serum, homogenized stomachs, and paws from adjuvant-induced arthritic rats. Compounds were administered twice daily on days 17 to 24, and paw tissues were recovered on day 25 after adjuvant injection for analysis. A, PGE2 levels in serum, stomachs, and paw. B, nitrite levels in serum and paw. C, TNF-α levels in paw. Data represent the mean ± S.E.M. (n = 6 animals/group). ★,p < 0.05; ★★, p < 0.01 with respect control group. C, control group; B, bolinaquinone; D, dexamethasone.

Effect on iNOS and COX-2 Protein Expression in Arthritic Paws.

We examined whether the decreased levels in nitrite and PGE2 levels in paw homogenates from bolinaquinone arthritic rats were associated with the inhibition of iNOS and COX-2 expression. As shown by Western blot (Fig.9), treatment with bolinaquinone potently reduced iNOS protein expression without affecting COX-2 expression measured in supernatants of homogenated arthritic paws on day 25, with respect to the control group. As expected, dexamethasone inhibited the protein expression of both enzymes.

Figure 9
View larger version:
Figure 9

Effect of bolinaquinone (6.3 mg/kg) and dexamethasone (2 mg/kg) on iNOS and COX-2 expression in homogenized rat paws from adjuvant-induced arthritic rats. Compounds were administered twice daily on days 17 to 24, and paw tissues were recovered on day 25 after adjuvant injection for analysis. The figure is representative of three similar experiments (n = 6 animals/group).

Radiographic Analysis of the Effect of Bolinaquinone on Adjuvant Arthritis.

A radiographic examination of hind paws from rats 25 days after adjuvant injection revealed bone matrix resorption and osteophyte formation at the joint margin (Fig.10A) in the arthritic control group. Bolinaquinone and dexamethasone markedly reduced the degree of bone resorption, soft tissue swelling, and osteophyte formation (Fig. 10, B and C).

Figure 10
View larger version:
Figure 10

Effect of bolinaquinone (6.3 mg/kg) and dexamethasone (2 mg/kg) on the radiographic progression of adjuvant-induced arthritis in the tibiotarsal joint of rats. Compounds were administered twice daily on days 17 to 24, and paw tissues were recovered on day 25 after adjuvant injection for radiographic examination. The figure is representative of three similar experiments (n = 6 animals/group).

Previous SectionNext Section

Discussion

Prostaglandins, leukotrienes, and nitric oxide are ubiquitous mediator systems exerting numerous vascular and inflammatory effects. Group II secretory PLA2 can act as a signaling agent contributing to the inflammatory response. This enzyme secreted at inflammatory sites becomes associated with cell surfaces and hydrolyzes phospholipids, thus releasing arachidonic acid, which enters the cell and participates in the increased generation of inflammatory lipid mediators like prostaglandins and leukotrienes (Balsinde et al., 1999).

Previous results indicate that bolinaquinone is a novel inhibitor of human synovial PLA2 with a higher potency for this enzyme than the reference inhibitor manoalide (Giannini et al., 2001). In addition, bolinaquinone is chemically very close to other molecules, such as avarol and avarone (Ferrándiz et al., 1994), which have been reported as potent anti-inflammatory agents. Notably, bolinaquinone, sharing with avarol and avarone a very similar sesquiterpenoid substructure moiety, differs in the benzenoid part attached to the sesquiterpene moiety. In this regard, bolinaquinone simultaneously contains in its structure the hydroquinone system present in avarol and the quinone system of avarone, which can confer to this compound some of its pharmacological properties.

Our in vitro results indicate that bolinaquinone is able to reduce LTB4 production in human neutrophils, as well as NO and PGE2 production in murine macrophages. The chemical structure of bolinaquinone, which contains a hydroquinone/quinone system with a low redox potential, is consistent with the notion that most lipoxygenase inhibitors are able to participate in redox reactions (Ford-Hutchinson et al., 1994; Silverman and Drazen, 1999). In this regard, it has been reported that although redox properties are essential for 5-LO redox inhibitory activity, the lipophilicity plays a dominant role in determining potency for this type of inhibitors (McMillan and Walker, 1992). It is noteworthy that the sesquiterpenoid substructure present in bolinaquinone confers on it a high lipophilicity. We have shown that this effect on LTB4 production is due to an enzymatic inhibition of 5-LO. Besides, bolinaquinone acted very potently as a topical or oral anti-inflammatory agent. The production of eicosanoids derived from the COX and 5-LO pathways was reduced by this marine product in different models of acute inflammatory response, such as mouse ear edema, carrageenan paw edema, and rat air pouch. This effect is, at least partly, a consequence of reduction in arachidonic acid availability through sPLA2 inhibition. Interestingly, bolinaquinone also inhibited group II sPLA2 in vivo in the 8-h zymosan-injected air pouch at a dose that did not affect neutrophil accumulation into the inflammatory exudate. The high reduction observed in LTB4 production would be a consequence of the dual inhibition of group II sPLA2 and 5-LO enzymatic activities. A high level of group II sPLA2 is present in inflammatory fluids and serum of patients from inflammatory diseases (Abe et al., 1997; Fourcade et al., 1998), and thus, the inhibition of sPLA2could control the excessive production of lipid mediators and exert protective effects in inflammatory disorders.

The model of adjuvant-induced arthritis in Lewis rats has been used for many years for evaluation of antiarthritic/anti-inflammatory agents (Winder et al., 1969) and is well characterized. In this model, bolinaquinone significantly affected the levels of PGE2 in the inflamed paw tissue during chronic inflammation, but it did not modify the content of this eicosanoid in serum or stomach. Thus, this marine compound unlike dexamethasone, selectively reduces PGE2 abnormally elevated during inflammation without reduction of protective levels in other tissues. Besides, bolinaquinone exhibited an important protection against body and spleen weight loss, unlike dexamethasone. In this model, rats develop a chronic swelling in multiple joints, with influx of inflammatory cells, erosion of joint cartilage and bone destruction of joint integrity and loss of function. This model of chronic inflammation is a complex response involving different mediators, and there is therefore a possibility of multiple interactions. In this regard, inflammatory cytokines or iNOS have a role in the development of inflammation (Stefanovic-Racic et al., 1993; Connor et al., 1995;Kollias et al., 1999).

Our data indicate that bolinaquinone is effective, by oral route, in the treatment of experimental chronic inflammation and that the inhibition of joint inflammation was accompanied by reduction of PGE2, NO, and TNF-α levels. In this regard, cytokines such as TNF-α and IL-1β are inducers of bone and cartilage destruction in the rheumatoid synovium, leading to the therapeutic application of anticytokine therapies in rheumatoid arthritis (Feldmann, 2002). TNF-α can stimulate the release of other cytokines, including IL-1β and chemokines, as well as the expression of adhesion molecules and inducible enzymes (Arias-Negrete et al., 1995). Our results suggest that reduction of NO production might be the consequence of iNOS protein expression inhibition, whereas PGE2 reduction, which is not due to an inhibition of COX-2 protein expression, would be related with the sPLA2 inhibitory activity of bolinaquinone, which would limit the bioavailability of arachidonic acid. The potent reduction in TNF-α content, exerted by bolinaquinone, seems to be based on the complex mechanism of action of this marine product. Whether bolinaquinone inhibits inducible NO synthase gene expression, as well as TNF-α production by interaction of nuclear factors or by other mechanisms, remains to be determined.

In summary, we have shown that bolinaquinone exerts inhibition of cytokine generation with a characteristic inhibitory profile on iNOS expression and eicosanoid production. The multipronged attack on inflammation and potency of this marine metabolite may have relevance for the inhibition of the inflammatory response and might be of potential interest in the search for new anti-inflammatory agents.

Previous SectionNext Section

Footnotes

  • This work was supported by Grant SAF2001–2639 from Comisión Interministerial de Ciencia y Tecnologı́a, Spanish Ministerio de Ciencia y Tecnologı́a. R.L. was the recipient of a Research Fellowship from FPI program of Spanish Ministerio de Ciencia y Tecnologı́a.

  • DOI: 10.1124/jpet.102.045278

  • Abbreviations:
    PLA2
    phospholipase A2
    sPLA2
    secreted PLA2
    PGE2
    prostaglandin E2
    COX-2
    cyclooxygenase-2
    5-LO
    5-lypoxigenase
    TPA
    12-O-tetradecanoylphorbol-13-acetate
    NO
    nitric oxide
    TNF-α
    tumor necrosis factor-α
    IL-1β
    interleukin-1β
    LTB4
    leukotriene B4
    iNOS
    inducible nitric oxide synthase
    MTT
    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
    A23187
    calcimycin
    ZM 230,487
    6-[[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy]methoyl]-1-ethylquinol-2-one
    • Received October 8, 2002.
    • Accepted November 26, 2002.
Previous Section
 

References

  1. ↵
    1. Abe T,
    2. Sakamoto K,
    3. Kamohara H,
    4. Hirano Y,
    5. Kuwahara N,
    6. Ogawa M
    (1997) Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer 74:245–250.
    CrossRefMedline
  2. ↵
    1. Arias-Negrete S,
    2. Keller K,
    3. Chadee K
    (1995) Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 208:582–589.
    CrossRefMedlineWeb of Science
  3. ↵
    1. Balsinde J,
    2. Balboa MA,
    3. Insel PA,
    4. Dennis EA
    (1999) Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 39:175–189.
    CrossRefMedlineWeb of Science
  4. ↵
    1. Bolognese B,
    2. McCord M,
    3. Marshall LA
    (1995) Differential regulation of elicited-peritoneal macrophage 14 kDa and 85 kDa phospholipase A2(s) by transforming growth factor-β. Biochim Biophys Acta 1256:201–209.
    Medline
  5. ↵
    1. Bomalaski JS,
    2. Clark MA
    (1993) Phospholipase A2 and arthritis. Arthritis Rheum 36:190–198.
    MedlineWeb of Science
  6. ↵
    1. Bustos G,
    2. Ferrándiz ML,
    3. Sanz MJ,
    4. Payá M,
    5. Alcaraz MJ
    (1995) A study of the novel anti-inflammatory agent florifenine. Topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn-Schmiedeberg's Arch Pharmacol 351:298–304.
    Medline
  7. ↵
    1. Carlson RP,
    2. O'Neill-Davis L,
    3. Chang J,
    4. Lewis AJ
    (1985) Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 17:197–204.
    CrossRefMedline
  8. ↵
    1. Connor JR,
    2. Manning PT,
    3. Settle SL,
    4. Moore WM,
    5. Jerome GM,
    6. Webber RK,
    7. Tjoeng FS,
    8. Currie MG
    (1995) Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 273:15–24.
    CrossRefMedlineWeb of Science
  9. ↵
    1. Edwards JCW,
    2. Sedgwick AD,
    3. Willoughby DA
    (1981) The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol 134:147–156.
    CrossRefMedlineWeb of Science
  10. ↵
    1. Feldmann M
    (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364–371.
    CrossRefMedlineWeb of Science
  11. ↵
    1. Ferrándiz ML,
    2. Sanz MJ,
    3. Bustos G,
    4. Payá M,
    5. Alcaraz MJ,
    6. De Rosa S
    (1994) Avarol and avarone, two new anti-inflammatory agents of marine origin. Eur J Pharmacol 253:75–82.
    CrossRefMedlineWeb of Science
  12. ↵
    1. Fonteh AN,
    2. Bass DA,
    3. Marshall LA,
    4. Seeds M,
    5. Samet JM,
    6. Chilton FH
    (1994) Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol 152:5438–5446.
    Abstract
  13. ↵
    1. Ford-Hutchinson AW,
    2. Gresser M,
    3. Young RN
    (1994) 5-Lipoxygenase. Annu Rev Biochem 63:383–417.
    CrossRefMedlineWeb of Science
  14. ↵
    1. Fourcade O,
    2. Le Balle F,
    3. Fauvel J,
    4. Simon MF,
    5. Chap H
    (1998) Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis. Adv Enzyme Regul 38:99–107.
    CrossRefMedlineWeb of Science
  15. ↵
    1. Franson R,
    2. Patriarca P,
    3. Elsbach P
    (1974) Phospholipid metabolism by phagocytic cells. Phospholipases A2 associated with rabbit polymorphonuclear leukocyte granules. J Lipid Res 15:380–388.
    Abstract
  16. ↵
    1. Garcia-Pastor P,
    2. De Rosa S,
    3. De Giulio A,
    4. Payá M,
    5. Alcaraz MJ
    (1999a) Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2. Br J Pharmacol 126:301–311.
    CrossRefMedline
  17. ↵
    1. Garcia-Pastor P,
    2. Randazzo A,
    3. Gomez-Paloma L,
    4. Alcaraz MJ,
    5. Payá M
    (1999b) Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. J Pharmacol Exp Ther 289:166–172.
    Abstract/FREE Full Text
  18. ↵
    1. Giannini C,
    2. Debitus C,
    3. Lucas R,
    4. Ubeda A,
    5. Payá M,
    6. Hooper JN,
    7. D'Auria MV
    (2001) New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions. J Nat Prod 64:612–615.
    CrossRefMedline
  19. ↵
    1. Gross SS,
    2. Levi R
    (1992) Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 267:25722–25729.
    Abstract/FREE Full Text
  20. ↵
    1. Hoult JR,
    2. Moroney MA,
    3. Payá M
    (1994) Actions of flavonoids and coumarins on lipoxygenase and cyclooxygenase. Methods Enzymol 234:443–454.
    MedlineWeb of Science
  21. ↵
    1. Jacques C,
    2. Bereziat G,
    3. Humbert L,
    4. Olivier JL,
    5. Corvol MT,
    6. Masliah J,
    7. Berenbaum F
    (1997) Posttranscriptional effect of insulin like growth factor I on interleukin 1β induced type II secreted phospholipase A2 gene expression in rabbit articular chondrocytes. J Clin Invest 99:1864–1872.
    Medline
  22. ↵
    1. Kang RY,
    2. Freire Moar J,
    3. Sigal E,
    4. Chu CQ
    (1996) Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 35:711–718.
    Abstract/FREE Full Text
  23. ↵
    1. Kaur H,
    2. Halliwell B
    (1994) Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 350:9–12.
    CrossRefMedlineWeb of Science
  24. ↵
    1. Kollias G,
    2. Douni E,
    3. Kassiotis G,
    4. Kontoyiannis D
    (1999) The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58 (Suppl 1) I32–I39.
  25. ↵
    1. Marcinkiewicz J,
    2. Grabowska A,
    3. Chain B
    (1995) Nitric oxide up-regulates the release of inflammatory mediators by mouse macrophages. Eur J Immunol 25:947–951.
    MedlineWeb of Science
  26. ↵
    1. McMillan RM,
    2. Walker ERH
    (1992) Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13:323–330.
    CrossRefMedline
  27. ↵
    1. Minami T,
    2. Tojo H,
    3. Shinomura Y,
    4. Matsuzawa Y,
    5. Okamoto M
    (1994) Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35:1593–1598.
    Abstract/FREE Full Text
  28. ↵
    1. Misko TP,
    2. Schilling RJ,
    3. Salvemini D,
    4. Moore WM,
    5. Currie MG
    (1993) A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214:11–16.
    CrossRefMedlineWeb of Science
  29. ↵
    1. Murakami M,
    2. Kudo I,
    3. Nakamura H,
    4. Yokoyama Y,
    5. Mori H,
    6. Inoue K
    (1990) Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A2. FEBS Lett 268:113–116.
    CrossRefMedline
  30. ↵
    1. Payá M,
    2. Terencio MC,
    3. Ferrándiz ML,
    4. Alcaraz MJ
    (1996) Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation. Br J Pharmacol 117:1773–1779.
    Medline
  31. ↵
    1. Pennanen N,
    2. Lapinjoki S,
    3. Palander A,
    4. Urtti A,
    5. Monkkonen J
    (1995) Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. Int J Immunopharmacol 17:475–480.
    CrossRefMedline
  32. ↵
    1. Pfeilschifter J,
    2. Schalkwijk C,
    3. Briner VA,
    4. van den Bosch H
    (1993) Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest 92:2516–2523.
  33. ↵
    1. Silverman ES,
    2. Drazen JM
    (1999) The biology of 5-lipoxygenase: function, structure and regulatory mechanisms. Proc Assoc Am Physicians 111:525–536.
    CrossRefMedline
  34. ↵
    1. Soriente A,
    2. De Rosa MMC,
    3. Scettri A,
    4. Sodano G,
    5. Terencio MC,
    6. Payá M,
    7. Alcaraz MJ
    (1999) Manoalide. Curr Med Chem 6:415–431.
    Medline
  35. ↵
    1. Stefanovic-Racic M,
    2. Stadler J,
    3. Evans CH
    (1993) Nitric oxide and arthritis. Arthritis Rheum 36:1036–1044.
    MedlineWeb of Science
  36. ↵
    1. Sugishita E,
    2. Amagaya S,
    3. Ogihara Y
    (1981) Anti-inflammatory testing methods: comparative evaluation of mice and rats. J Pharmacobio-Dynam 4:565–575.
    Medline
  37. ↵
    1. Tateson JE,
    2. Randall RW,
    3. Reynolds CH,
    4. Jackson WP,
    5. Bhattacherjee P,
    6. Salmon JA,
    7. Garland LG
    (1988) Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 94:528–539.
    Medline
  38. ↵
    1. Taurog JD,
    2. Argentieri DC,
    3. McReynolds RA
    (1988) Adjuvant arthritis. Methods Enzymol 162:339–355.
    MedlineWeb of Science
  39. ↵
    1. Vadas P,
    2. Pruzanski W
    (1986) Biology of disease. Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest 55:391–404.
    MedlineWeb of Science
  40. ↵
    1. Winder CV,
    2. Lembke LA,
    3. Stephens MD
    (1969) Comparative bioassay of drugs in adjuvant-induced arthritis in rats: flufenamic acid, mefenamic acid and phenylbutazone. Arthritis Rheum 12:472–482.
    MedlineWeb of Science
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print December 13, 2002, doi: 10.1124/jpet.102.045278 JPET March 1, 2003 vol. 304 no. 3 1172-1180
  1. AbstractFree
  2. » Full Text
  3. Full Text (PDF)
  4. All Versions of this Article:
    1. jpet.102.045278v1
    2. 304/3/1172 most recent

Responses

  1. Submit a response
  2. No responses published

Navigate This Article

Current Issue

  1. November 2009, 331 (2)
  1. Current Issue
  1. Alert me to new issues of JPET